GYRE

Gyre Therapeutics (GYRE)

About Gyre Therapeutics (GYRE)

Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis). The firm operates through the BC and Gyre segments. The company was founded on March 7, 1997 and is headquartered in San Diego, CA.

Details

Daily high

$7.47

Daily low

$7.20

Price at open

$7.21

52 Week High

$11.78

52 Week Low

$6.57

Market cap

685.7M

Dividend yield

0.00%

Volume

149

Avg. volume

62,196

P/E ratio

312.83

Gyre Therapeutics News